Why ASX Medical Imaging Stocks Are Beating the AI Selloff And What It Means for Healthcare Investors

While tech stocks broadly sold off on AI disruption concerns, Australian medical imaging companies kept growing, posting record revenues, winning major global contracts, and quietly expanding their footprint inside some of the world's most prestigious hospitals.

For investors willing to look past the headlines, that disconnect is worth understanding.

Why Everyone Got Scared And Why It May Be Overdone

The worry is simple: if AI can do what software does, then software companies lose their value. That logic hit ASX healthcare technology stocks hard in early 2026, with Pro Medicus (ASX: PME) falling nearly 65% from its 2025 peak despite reporting revenue growth of 28.4% in its most recent half-year results.

That is a striking gap between the share price and the underlying business.

The reality in medical imaging is more nuanced than the market is pricing in. AI is not replacing radiologists. It is helping them handle more work. Imaging volumes globally are rising faster than the medical workforce can keep up with. AI tools are being used to close that gap, not eliminate the people who interpret the scans.

Pro Medicus CEO Sam Hupert has noted that AI in radiology is being used to play catch-up rather than replace clinicians who are already in high demand.

‍

What Makes This Sector Hard to Disrupt

Medical imaging software is not like a consumer app you can delete and replace overnight. Hospitals take years to evaluate, procure, and implement new platforms. The switching costs are enormous. The legal and liability risks are even higher.

Healthcare institutions are deeply risk-averse. Any AI challenger must navigate security, explainability, liability, and reimbursement hurdles that go well beyond what consumer technology faces.

That friction is actually a feature for long-term investors. Once a hospital is running on your platform, they tend to stay. Contracts in this space typically run five to ten years.

Two ASX Companies Leading the Shift

Pro Medicus (ASX:PME) is the standout name. The company secured seven new contracts totalling over A$280 million in the first half of FY26, with forward contracted revenue exceeding A$1,080 million over five years. Perhaps most telling is its underlying EBIT margin of 72.6%, one of the highest of any software company on the ASX, meaning nearly three quarters of every revenue dollar flows through to operating profit. Its Visage 7 platform is designed to integrate AI tools built by others, meaning it benefits from the AI boom without being threatened by it.

Mach7 Technologies (ASX:M7T) is the smaller, higher-risk play. Under CEO Teri Thomas, who took the helm in July 2025 after leading Volpara Health Technologies to a successful acquisition, the company unveiled Flamingo, an AI-powered orchestration platform designed to modernise imaging workflows without costly system replacements. Critically, the first Flamingo customer contract was already signed in the December 2025 quarter, proving the technology is live and generating real commercial interest. It represents a credible turnaround story with meaningful upside if execution holds.

These two companies serve the same broad market but sit at very different points on the risk curve. PME is the quality compounder; M7T is the growth bet.

What Investors Should Consider

The AI selloff in healthcare tech has created an unusual situation: companies with strong earnings growth, multi-year contracted revenue, and global market positions are being punished because of sector-wide sentiment rather than company-specific problems.

That does not mean the risks are zero. PME's valuation, even after the pullback, remains elevated. M7T is still in the early stages of its turnaround. And genuine AI disruption, while not imminent, remains a long-term variable worth monitoring.

Key takeaways for investors:

• Medical imaging software has structural moats that make it resistant to rapid AI disruption
• PME's 72.6% EBIT margin and A$1,080 million contracted revenue pipeline provide unusual earnings visibility
• M7T's first live Flamingo contract offers a higher-risk entry point into the same secular trend

For investors seeking exposure to healthcare technology with genuine growth credentials, the current environment may be worth a closer look.

‍

ASR's Investing Report covers high-growth ASX opportunities across healthcare, technology, and emerging sectors. Explore the Investing Report to see a detailed analysis of companies navigating the AI transition.

Download ASR's free Top-3 Stocks & Market Outlook Report for a broader view of where opportunities are emerging across the ASX right now.

‍